Navigation Links
Anti-inflammatory drugs (coxibs) interfere with aspirin's clotting ability -- Ben-Gurion U.
Date:12/23/2009

BEER-SHEVA, ISRAEL -- December 23, 2009 -- A new study conducted at Ben-Gurion University of the Negev (BGU) reveals that Celebrex and other anti-inflammatory coxib medications may counter the positive effects of aspirin in preventing blood clots.

The research, published in the Proceedings of the National Academy of Sciences (PNAS), indicates that people who are taking aspirin and coxibs together are in fact inhibiting the aspirin's effectiveness in preventing heart attacks and strokes.

"This finding strongly suggests that humans who are consuming coxibs and a low dose of aspirin simultaneously are exposed to a greater risk of cardiovascular events," said Professor Gilad Rimon, Department of Clinical Pharmacology, Ben-Gurion University of the Negev in Israel.

In the past decade, a new group of anti-inflammatory drugs, coxibs, which include Celebrex and Arcoxia was developed to treat arthritis as well as other pain. Arthritis patients who take Celebrex are instructed to take low-dose aspirin to counteract Celebrex's own potential clot-promoting effect.

Aspirin is the oldest and one of the most effective non steroidal anti-inflammatory drugs. It is also well known for its ability to prevent the blood clots that can potentially lead to heart attack and stroke. Therefore, doctors often advise patients who are more prone to heart-related illnesses to take a daily tablet of low dose aspirin (81 mg). Approximately, 50 million Americans take aspirin every day to reduce their risk of cardiovascular diseases.

Now, the BGU research suggests that in the presence of coxibs, asprin's protective role in preventing new blood clots is blunted.

This finding mirrors a cooperative study conducted at the University of Michigan, Ann Arbor that showed for the first time that Celebrex and other coxibs directly interfere with the protective qualities of aspirin.


'/>"/>

Contact: andrew lavin
andrewlavin@alavin.com
516-944-4486
American Associates, Ben-Gurion University of the Negev
Source:Eurekalert

Page: 1

Related biology news :

1. Anti-inflammatory drug blocks brain plaques
2. The quest for specific anti-inflammatory treatment
3. Funxional successfully completes initial clinical trial of FX125L, an anti-inflammatory drug with a novel mechanism of action
4. Carnegie Mellon scientists develop nanogels that enable controlled delivery of carbohydrate drugs
5. Socioeconomic position associated with effectiveness of HIV drugs
6. Using green chemistry to deliver cutting-edge drugs
7. MIT model could improve some drugs effectiveness
8. Plants can be used to study how and why people respond differently to drugs
9. Insulins brain impact links drugs and diabetes
10. Scientists unveil structure of molecular target of many drugs
11. Market testing of dietary supplements and drugs underscores value of USPs public health programs
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/11/2017)... 11, 2017 Crossmatch®, a globally-recognized leader ... today announced that it has been awarded a ... Activity (IARPA) to develop next-generation Presentation Attack Detection ... "Innovation has been a driving force within Crossmatch ... allow us to innovate and develop new technologies ...
(Date:4/11/2017)... , April 11, 2017 No ... but researchers at the New York University Tandon ... of Engineering have found that partial similarities between ... systems used in mobile phones and other electronic ... The vulnerability lies in the fact ...
(Date:4/6/2017)... , April 6, 2017 Forecasts ... ANPR, Document Readers, by End-Use (Transportation & Logistics, Government ... Oil, Gas & Fossil Generation Facility, Nuclear Power), Industrial, ... Other) Are you looking for a definitive ... ...
Breaking Biology News(10 mins):
(Date:6/28/2017)... ... June 28, 2017 , ... Ovation Fertility continues ... for presentation at the 33rd Annual Meeting of the European Society of ... the world’s top thought leaders in reproductive medicine – are expected to attend ...
(Date:6/27/2017)... ... , ... The recent vote by the American Medication Association to align with ... patients and hopefully sheds new light on the way health insurers, governments and the ... founding partner of Texas Fertility Center . , “This designation is something ...
(Date:6/27/2017)... (PRWEB) , ... June 27, 2017 , ... ... license agreement whereby DuPont gains exclusive rights to the ERS patent portfolio covering ... was formed to commercialize the foundational intellectual property (IP) of the CRISPR-Cas technology ...
(Date:6/23/2017)... IA (PRWEB) , ... June 23, 2017 , ... Biova, ... Henig, Ph.D. has joined Biova’s Board of Directors. Dr. Henig will bring a wealth ... Dr. Henig has served as the Chief Technical and Scientific Officer of four major ...
Breaking Biology Technology: